Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

NCT03706287 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Metastatic

Interventions

DRUG: anlotinib 8mg + AP/PC
DRUG: anlotinib 10mg + AP/PC
DRUG: anlotinib 12mg + AP/PC
DRUG: anlotinib + AP/PC

Sponsor

Sichuan Cancer Hospital and Research Institute

Collaborators

[object Object]